Edition:
India

Pernix Therapeutics Holdings Inc (PTX.OQ)

PTX.OQ on NASDAQ Stock Exchange Global Market

2.37USD
1:30am IST
Change (% chg)

$0.06 (+2.60%)
Prev Close
$2.31
Open
$2.35
Day's High
$2.37
Day's Low
$2.31
Volume
8,679
Avg. Vol
19,709
52-wk High
$7.15
52-wk Low
$2.00

Latest Key Developments (Source: Significant Developments)

Pernix Therapeutics Reports Q4 Loss Per Share $2.78
Friday, 9 Mar 2018 

March 8 (Reuters) - Pernix Therapeutics Holdings Inc ::PERNIX THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 REVENUE ROSE 38 PERCENT TO $41.5 MILLION.Q4 LOSS PER SHARE $2.78.  Full Article

Pernix Announces Launch Of Authorized Generic Of Treximet
Saturday, 17 Feb 2018 

Feb 16 (Reuters) - Pernix Therapeutics Holdings Inc ::PERNIX THERAPEUTICS ANNOUNCES LAUNCH OF AUTHORIZED GENERIC VERSION OF TREXIMET® BY COMPANY’S SUBSIDIARY, MACOVEN PHARMACEUTICALS.PERNIX THERAPEUTICS HOLDINGS INC - ‍DESPITE LAUNCH OF AN AUTHORIZED GENERIC, PERNIX EXPECTS A SIGNIFICANT DECREASE IN SALES OF TREXIMET IN 2018​.  Full Article

Pernix Therapeutics Will Reduce Workforce By 41 Employees
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Pernix Therapeutics Holdings Inc ::PERNIX THERAPEUTICS HOLDINGS INC - WILL REDUCE WORKFORCE BY 41 EMPLOYEES; MAJORITY EXPECTED TO BE WITH CO'S SALES FORCE & COMMERCIAL INFRASTRUCTURE.PERNIX THERAPEUTICS - ‍EXPECTS TO COMPLETE REALIGNMENT PLAN TO REDUCE OPERATING COSTS, ALIGN WORKFORCE ON JAN 5, 2018 - SEC FILING​.  Full Article

Pernix Therapeutics files for mixed shelf offering of up to $150 mln
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - Pernix Therapeutics Holdings Inc ::Pernix Therapeutics Holdings files for mixed shelf offering of up to $150 million - SEC filing‍​.  Full Article

Pernix Therapeutics posts Q3 revenue of $40.5 mln
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Pernix Therapeutics Holdings Inc :Pernix Therapeutics reports third quarter 2017 financial results.Q3 revenue fell 2 percent to $40.5 million.  Full Article

Pernix Therapeutics announces sale of non-core product
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Pernix Therapeutics Holdings Inc :Pernix Therapeutics announces sale of non-core product.Pernix Therapeutics Holdings Inc - ‍sale of a non-core product Cedax to SI Pharmaceuticals LLC, for $2 million in gross cash proceeds​.  Full Article

Pernix Therapeutics reports qtrly net loss per common share $2.16
Friday, 28 Jul 2017 

July 27 (Reuters) - Pernix Therapeutics Holdings Inc :Pernix Therapeutics reports second quarter 2017 financial results and provides business update.Q2 revenue $34.3 million versus I/B/E/S view $40.3 million.Pernix Therapeutics Holdings Inc - Qtrly net loss per common share $2.16 ‍​.  Full Article

Pernix Therapeutics files for resale of up to 10.1 million shares of common stock by selling stockholders - SEC filing‍​
Monday, 24 Jul 2017 

July 24 (Reuters) - Pernix Therapeutics Holdings Inc :Pernix Therapeutics files for resale of up to 10.1 million shares of common stock by selling stockholders - SEC filing‍​.  Full Article

Pernix Therapeutics Holdings expects Q2 revenues to be between $33 mln and $35 mln
Friday, 21 Jul 2017 

July 20 (Reuters) - Pernix Therapeutics Holdings Inc :Pernix Therapeutics pre-announces certain preliminary second quarter 2017 financial results.Sees Q2 2017 revenue $33 million to $35 million.Sees Q2 2017 revenue down 5 to 10 percent.Pernix Therapeutics Holdings Inc says Q2 2017 net revenues are expected to be between $33.0 million and $35.0 million.Pernix Therapeutics Holdings Inc - ‍Net loss for Q2 of 2017 is expected to be between $20.5 million and $24.5 million​.  Full Article

Pernix Therapeutics qtrly loss per share $2.94
Tuesday, 16 May 2017 

May 15 (Reuters) - Pernix Therapeutics Holdings Inc ::Pernix Therapeutics reports first quarter 2017 financial results and provides business update.Q1 revenue fell 8.6 percent to $29.7 million.Pernix Therapeutics Holdings Inc - qtrly loss per share $2.94.Pernix Therapeutics -net product revenues - other products increased by $0.1 million, or approximately 1%, during three months ended March 31, 2017.Pernix Therapeutics Holdings Inc says total principal amount of debt outstanding at March 31, 2017 was approximately $320.8 million.Pernix Therapeutics -agreed that a failure to repay all borrowings under revolving credit facility on or before July 31, would constitute an event of default.  Full Article

BRIEF-Pernix Therapeutics Announces Participation In Lead Bid Worldwide Rights Of Contrave

* PERNIX THERAPEUTICS ANNOUNCES PARTICIPATION IN LEAD BID FOR ACQUISITION OF WORLDWIDE RIGHTS TO CONTRAVE® FOR WEIGHT LOSS